News|Articles|April 7, 2026
How PBMs are helping patients stay on GLP-1s
Author(s)Denise Myshko
Fact checked by: Cheney Gazzam Baltz
PBMs have launched clinical programs pairing GLP-1 prescriptions with pharmacist coaching, nutrition support, behavioral health partnerships, and digital tools to improve adherence and outcomes.
Advertisement
Advertisement
Despite a high demand for glucagon-like peptide 1 (GLP-1) drugs for weight loss, patients still struggle to remain on therapy. Insurance coverage restrictions are common for GLP-1 drugs, such as semaglutide (Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes and Zepbound for weight loss), as well as the newly approved oral Foundayo (orforglipron).
Advertisement
Advertisement